Novel T Cell Therapy Targeted Resistant Glioblastoma
Researchers found that a new cell-based therapy could shrink chemotherapy-resistant brain tumors in preclinical models.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Do you believe new cell therapies offer a promising path for treating resistant cancers?
Scientists have reported that a new type of immune therapy using gamma-delta (γδ) T cells successfully reduced tumor size in models of aggressive, chemotherapy-resistant glioblastoma. This research, presented at the Japanese Cancer Association meeting, suggests a potential new path for treating tumors that typically resist standard care.
Why it matters
Glioblastoma cells that express the MGMT protein are notoriously resistant to standard chemotherapy because they effectively reverse DNA-damage treatments. This research seeks to identify new ways to combat these resilient tumors by targeting cells that standard therapies struggle to eliminate.
In a preclinical study using three glioblastoma cell lines, researchers found that γδ T cells exhibited higher cancer-killing activity compared to conventional αβ T cells. The therapy reduced tumor size and improved survival in an intracranial glioblastoma model.
The players
SL Science
A biotechnology firm focused on developing cell-based immunotherapies for oncology.
Taipei Medical University
A research-focused university that collaborates on advanced cancer immunology studies.
Japanese Cancer Association
A professional scientific organization that hosts annual meetings to discuss advancements in cancer research.
The details
The therapy functions by utilizing γδ T cells, which recognize general stress signals expressed by cancer cells instead of requiring a specific antigen to identify their targets. By bypassing the need for a singular antigen, these cells can potentially identify and kill glioblastoma cells that have evolved resistance to chemotherapy. Researchers verified this activity through real-time analysis across three distinct cell lines to measure the reduction of tumor cells.
Timeline
July 2026: Results regarding in vivo tumor growth were presented in Melbourne.
August 2026: Clinical development requirements were published.
September 24-26, 2026: The research was presented at the 85th Annual Meeting of the Japanese Cancer Association.
Health Landscape
This research is part of the broader evolution of T cell-based immunotherapies, which aim to move beyond the limitations of current cancer treatments. It seeks to improve upon existing standards by addressing the specific mechanisms that make glioblastoma cells resistant to chemotherapy.
This development represents a preliminary stage of research and is not currently available for patient care. If you or a loved one are managing glioblastoma, discuss the latest clinical trial options and experimental treatment eligibility with a neuro-oncologist.
The takeaway
While this preclinical research shows promise in targeting chemotherapy-resistant brain tumors, it remains in the early stages of development. Patients should focus on maintaining open communication with their medical team regarding standard treatment options and emerging trial opportunities.
Further reading
For more information on current treatment trends and emerging developments in oncology, visit our Cancer section.
More information
Find additional information on the company’s ongoing research efforts on the SL Science company website.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new cell therapies offer a promising path for treating resistant cancers?
